PMID- 34446966
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220426
IS  - 1998-3611 (Electronic)
IS  - 0019-5154 (Print)
IS  - 0019-5154 (Linking)
VI  - 66
IP  - 3
DP  - 2021 May-Jun
TI  - Intravenous Immunoglobulin: Revisited - My Experience.
PG  - 329
LID - 10.4103/ijd.IJD_559_17 [doi]
AB  - BACKGROUND: Many a times while treating dermatoses conventional therapies are 
      either contraindicated or not effective. Intravenous immunoglobulin (IVIG) is a 
      good alternative available to tide over crises. METHOD: Over the last 15 years of 
      my practice I have used IVIg in various severe or recalcitrant diseases 
      (including TEN, autoimmune blistering disease,connective tissue disorders , 
      chronic urticaria etc) which were either unresponsive to conventional modality of 
      therapy or primary therapy could not be given because of co-morbidities. RESULT: 
      IVIg a sterile, highly purified preparation containing more than 95% unmodified 
      IgG,was first approved by FDA in 1981 for 6 diseases. As mentioned above in many 
      circumstances we reached a situation when either conventional primary therapy was 
      contraindicated or patients were not responding. IVIg came to our rescue in large 
      number of conditions to tide over the crisis and also created the environment 
      leading to conventional therapy becoming effective. Very few minor side effects 
      like low grade fever and myalgia were observed in very few cases. No serious or 
      severe side effects were seen, however , one has to be prepared for anaphylactic 
      reaction which is a theoretical possibility. CONCLUSION: It can be said that IVIg 
      though not a magic drug, is a very effective tool available in the armamentarium 
      of Dermatologists to treat plethora of chronic and intractable dermatoses.
CI  - Copyright: (c) 2021 Indian Journal of Dermatology.
FAU - Vaishampayan, Sanjeev S
AU  - Vaishampayan SS
AD  - Department of Dermatology, Index Medical College, Indore, Madhya Pradesh, India.
FAU - Bhati, Surendra Singh
AU  - Bhati SS
AD  - Department of Dermatology, Index Medical College, Indore, Madhya Pradesh, India.
FAU - Lachhiramani, Radha R
AU  - Lachhiramani RR
AD  - Department of Dermatology, Index Medical College, Indore, Madhya Pradesh, India.
FAU - Shrivastava, Shivank
AU  - Shrivastava S
AD  - Department of Dermatology, Index Medical College, Indore, Madhya Pradesh, India.
FAU - Jain, Prateek
AU  - Jain P
AD  - Department of Dermatology, Index Medical College, Indore, Madhya Pradesh, India.
FAU - Raghuwanshi, Ajay Singh
AU  - Raghuwanshi AS
AD  - Department of Dermatology, Index Medical College, Indore, Madhya Pradesh, India.
LA  - eng
PT  - Journal Article
PL  - India
TA  - Indian J Dermatol
JT  - Indian journal of dermatology
JID - 0370750
PMC - PMC8375533
OTO - NOTNLM
OT  - Chronic dermatoses
OT  - indications
OT  - intravenous immunoglobulin-revisited
COIS- There are no conflicts of interest.
EDAT- 2021/08/28 06:00
MHDA- 2021/08/28 06:01
PMCR- 2021/05/01
CRDT- 2021/08/27 06:50
PHST- 2021/08/27 06:50 [entrez]
PHST- 2021/08/28 06:00 [pubmed]
PHST- 2021/08/28 06:01 [medline]
PHST- 2021/05/01 00:00 [pmc-release]
AID - IJD-66-329c [pii]
AID - 10.4103/ijd.IJD_559_17 [doi]
PST - ppublish
SO  - Indian J Dermatol. 2021 May-Jun;66(3):329. doi: 10.4103/ijd.IJD_559_17.